History

The Turnaround That Worked, Then Broke

For five years Molina was a textbook turnaround success — a profitability-first CEO took over a damaged company in 2017, built a $43B premium-revenue pure-play government managed-care operator, and compounded adjusted EPS from a low single-digit base to $20.88 in FY2023. Then, in eighteen months, that story shattered: full-year 2025 adjusted EPS came in at $11.03 (vs. the original $24.50 guide), 2026 has been reset to ≥$5.00, and the lead risk factor in the 10-K has migrated from "COVID we cannot foresee" to "the rates states pay us may not cover our medical costs." This page is about both arcs — what the team did right, what management said as the story turned, and whether the credibility built across the first chapter can survive what happened in the second.

The Arc at a Glance

The blue line is what Molina actually earned (adjusted). The red line is what management originally guided for that fiscal year, set at the beginning of the year and never revised in their original guidance press release. The gap that opens in 2025 — $13.47/sh of adjusted EPS that simply did not arrive — and the further 76% reduction in 2026 are the central facts of this section.

Two Chapters Under One CEO

The current CEO, Joseph M. Zubretsky, took the role in November 2017 after a board-driven firing of co-CEO siblings J. Mario Molina (CEO) and John Molina (CFO) — a remarkable shakeup of the founding family that had run the company for 37 years. The business he inherited was not high quality: the Marketplace segment had blown up in 2016–2017, ACA exposure was draining capital, the medical care ratio was elevated, and the stock had lost roughly half its value in the prior twelve months. Zubretsky did not inherit a compounder — he built one out of a damaged Medicaid franchise.

Same CEO; two entirely different operating records. The investment debate is whether Chapter II is a temporary industry cycle that the Chapter I operator can navigate, or whether it is the consequence of Chapter I capital decisions (especially the Bright Health Medicare and ConnectiCare acquisitions, and the aggressive Marketplace re-expansion) that came home to roost.

Chapter I — What the Turnaround Actually Did (2018-2023)

The first six years under Zubretsky were the period a buy-side reader would have bought this stock for. Three things happened in parallel:

One — disciplined exit and re-entry of unprofitable segments. Zubretsky's first big act was retrenching the Marketplace business that had cratered under the prior regime. The 2017–2018 cleanup is pre-period for this dataset, but the 2021 Marketplace re-blow-up is fully visible: SEP-driven membership exploded from 318K to 728K and the MCR jumped 820 bps to 86.9%. Within twelve months they cut Marketplace membership by ~52% and the next year (2023) Marketplace MCR collapsed to 75.3% — 1,190 bps of margin restoration in a single year. This is what professional underwriting discipline looks like, and it built the credibility that would later be spent.

Two — the acquisition roll-up. From 2020 to early 2024 Molina closed seven sizable transactions adding ~$11B of premium revenue at an average purchase price disclosed as ~22% of premium:

The 22%-of-premium discipline boast disappears from the disclosure after FY2023. The "$10–11B from seven transactions" line gets trimmed to "more than $10 billion" with no deal count by FY2025. The two most recent acquisitions — Bright Health (Jan 2024) and ConnectiCare (Feb 2025) — are the two named drag-factors in the 2024–2025 collapse. Bright Health's MAPD book is being entirely exited for 2027. The pattern is unsubtle: the earlier deals integrated cleanly; the deals closed at the top of the M&A cycle are being unwound.

Three — durable double-digit ROE and credibility for long-term targets. By the FY2022 10-K, management was writing: "We are pleased with the continued success of our profitable growth strategy. Our performance on Medicaid state procurements in 2022 was exceptional, as we were successful on every request for proposal response that we submitted." By FY2023 the strategy section had been re-pitched with explicit KPIs — 75% new contract win rate, 100% re-procurement win rate, ~5% pre-tax margin, ~$11B of acquired premium at 22% of premium — and the headline 13%-15% adjusted EPS growth target through 2026. This was the framing that survived through Q1 2025 and was then quietly retired.

Chapter II — The Rupture (2024-2026)

The numbers broke in Q2 2024. The story did not break for another twelve months.

Every line bends the wrong way in 2024–2025. The blue line — consolidated MCR — moves from 88.0% to 91.7% in three years. On a $43B premium base, that 370 bps deterioration equals roughly $1.6B of vanished medical margin — almost exactly the gap between FY2024's $1.18B of net income and FY2025's $472M.

The Quiet Twelve Months

Management told a more confident story than the data warranted for four consecutive quarters. Here is the gap:

A reader watching only the headlines would have seen four "in-line" prints and a $0.85/sh annual miss. A reader watching the segment MCRs would have seen a structural deterioration in the load-bearing Medicaid business, papered over with Marketplace outperformance, investment income, and an aggressive buyback program. The "successfully navigated unprecedented redetermination" line in July 2024 is the smoking gun: it was declared past-tense before the acuity-mix shift had played through.

The Break and the Re-pricing

The Q2 2025 print was the moment the company's six-year story of execution-credibility ended. The CEO chose the phrase "temporary dislocation between premium rates and medical cost trend which has recently accelerated" — three carefully chosen words: temporary, dislocation, recently. None held up. By Q3, Marketplace MCR was 95.6% (vs. 71.6% one year earlier), Medicare 93.6%, and the preliminary 2026 outlook was flat-to-2025 at roughly $14. By Q4 even that was halved to ≥$5.00, the Marketplace business was being cut 50% for 2026, and the entire MAPD product line — the centerpiece of the Bright Health Medicare deal closed only 24 months earlier — was put down for 2027.

Guidance vs Delivery — The Scorecard

Of 12 numerical FY-level guides issued for 2024 and 2025 by the original press release each year, 2 were beat (top-line revenue, masking margin failure) and 10 were missed. The two highest-stakes promises — the 13-15% long-term adjusted EPS growth target set in the FY2023 strategy refresh, and the $24.50 FY25 EPS guide — were both effectively withdrawn. The growth target was last printed in the Q1 2025 press release and conspicuously absent from Q2 2025 onward, replaced by a softer "long-term performance outlook."

What Management Stopped Saying

A history that only tracks what management says today misses the deeper signal — what they quietly stopped saying. Three phrases anchored the 2023–2024 story and were retired without comment:

And three phrases that newly appeared:

"Temporary dislocation" (Q2 2025) — the chosen frame for the rupture. Definitional, because "temporary" implies management knows the magnitude and the duration. Neither has held up.

"Trough year" (Q4 2025) — cycle/industry framing. Externalizes a problem that twelve months earlier was being described as a Molina opportunity ("embedded earnings").

"Imbalance between rates and trend" (Q4 2025) — locates the cause at the state-rate-setting process, not in Molina's underwriting. Convenient, and partially true.

The Risk-Factor Migration — Where the Real Fear Lives

The single most diagnostic five-year shift in the entire corpus is the lead risk factor in the 10-K:

The most important reader-takeaway: the lead risk factor in FY2021 — COVID, an external exogenous shock — has migrated by FY2025 to the actuarial soundness of state Medicaid rates, which is the foundational economic premise of the entire pure-play Medicaid managed-care business model. Risk #1 used to come from outside the firm; it now comes from inside the contracts that define the firm. The structural admission is unsubtle and is the single most important sentence in the five-year filing record.

The Embedded Earnings Tell

One disclosed metric escalates exactly as the base earnings collapse:

When Q4 2024 missed its guide by 3.6%, management introduced a new non-GAAP metric — "new store embedded earnings" of $7.75/sh, attributed to a 2026-2028 window. As actual earnings have collapsed (from $22.65 to $11.03), the embedded earnings figure has risen (from $7.75 to >$11.00) and the window has rolled forward by a year. By FY26 reset, the embedded earnings claim is larger than the entire base guide. This is the analytical pattern to watch — promises pushed further into the future at exactly the moment present promises break. It is not necessarily dishonest; it is precisely how management retains a story when the near-term numbers fail. But it requires investor faith in management's ability to under-promise and over-deliver — faith that the 2024–2025 record has materially impaired.

The Capital-Return Decisions That Don't Age Well

Diluted share count was reduced from 58.6M (FY21) to 51.1M (FY26 guide) — roughly 12% — at a cost of over $2.5B in buybacks. The deployment timing is the diagnostic:

The first $1B (Q3 + Q4 2024) was executed at an average price around $320/share while the underlying Medicaid MCR was clearly deteriorating and the company was carrying only $195M of parent cash. The Q1 2025 $500M was at ~$298/share, three months before the guide cut. The Q3 2025 $500M was at $175/share — bought into the rupture, which improves the average but does not reverse the earlier judgment error. The "buybacks at $341 while operations were quietly deteriorating" episode is the second-most-important credibility hit after the dropped 13-15% growth target.

Credibility Verdict

A 4 reflects two opposing facts that must be held simultaneously.

The case for higher (the Chapter I record): From 2018 to early 2024 this team executed a textbook profitability-first turnaround on a damaged Medicaid franchise. They demonstrated they can read an underwriting cycle (the 2021–2022 Marketplace exit), integrate disciplined acquisitions (Magellan, Affinity, Cigna TX, AgeWell, My Choice), and earn durable double-digit ROE in a low-margin business. The strategic logic of focusing exclusively on government programs was correct and proven. If credibility were judged on the 2018–2023 record alone, the score would be 8/10.

The case for lower (the Chapter II record):

1. Material missed guidance. FY2024 adjusted EPS missed by 3.6% with no mid-year warning. FY2025 adjusted EPS missed the original guide by 55% ($11.03 vs. $24.50), and missed the third cut guide as well.
2. Delayed acknowledgment. The Medicaid MCR fractured in Q2 2024; the guide held at "reaffirmed" for three more quarters before the year-end miss. Q2 2024's "successfully navigated unprecedented redetermination" was wrong at the moment it was said.
3. Capital deployed into deterioration. $1.5B of buybacks across Q3 2024–Q1 2025 at an average price near $320/share, ahead of a guide cut that would take the stock below $200.
4. Two top-of-cycle acquisitions are being unwound. Bright Health's MAPD product is being exited entirely (effective 2027); ConnectiCare is being cited as a Marketplace MCR drag less than 12 months after close.
5. Future story replacing present story. "Embedded earnings" is raised every time current earnings fall, with the realization window rolled forward. By FY26 reset, the embedded earnings figure ($11/sh) is larger than the base guide ($5).
6. Quantitative pledges withdrawn without acknowledgment. The 13-15% long-term adjusted EPS growth target — the centerpiece of the FY2023 strategy refresh — vanished from disclosure between Q1 and Q2 2025.

The synthesis: Zubretsky's team did the hard thing well (turn around a damaged franchise) and the easy thing badly (read a normalization cycle while their growth incentives pushed acquisitions and Marketplace re-expansion). Industry peers (Centene, Elevance, Humana) have all experienced the same rate-trend imbalance, so some of the 2025 pain is industry-cycle rather than Molina-specific. But the magnitude of Molina's miss — and the way the company communicated through the deterioration — exceed what an industry-cycle explanation alone supports.

Score: 4/10, with directional risk to the upside if the May 8, 2026 Investor Day delivers a credible re-pitch and 2026 operational results stabilize, and to the downside if the $5.00 FY26 floor breaks. The number reflects credibility-as-of-today; the trajectory of that credibility depends entirely on the next four quarters.

What the Story Is Now — and What to Believe vs Discount

The narrative today is simpler, smaller, and more stretched than it was twenty-four months ago. Simpler, because the strategy is now openly defensive — exit MAPD, halve Marketplace, lean on Medicaid re-procurements, and absorb the rate cycle. Smaller, because the 2026 base is half of 2024's. More stretched, because the story now depends on a "trough" framing whose duration management does not control (state rate-setting cycles), on a "$11+ embedded earnings" claim that no investor will fully credit until current earnings inflect, and on the May 8 Investor Day to re-pitch a long-term target that has been withdrawn without replacement.

Credibility is deteriorating, not improving — but the rate of deterioration appears to have stopped at Q1 2026. The Q1 2026 reaffirm and the operating cash flow rebound ($1.08B) are the first non-deteriorating data points in eighteen months. The Investor Day on May 8, 2026 is the explicit pivot moment. A real read on whether this is a 2017-style turnaround that worked once and will work again, or a permanent re-rating, requires watching the next two prints alongside the IR deck. Until then, the page on this management team is: they earned trust over six years, spent it in eighteen months, and have been given one chance to start earning it back.